ADMA Biologics is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of Primary Immune Deficiency Disease and certain infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.  Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.

TypePublic
HQRamsey, US
Founded2004
Size (employees)92 (est)
Websiteadmabiologics.com
ADMA Biologics was founded in 2004 and is headquartered in Ramsey, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at ADMA Biologics

Bryant E. Fong

Bryant E. Fong

Director
Dov Goldstein

Dov Goldstein

Director
James Mond

James Mond

Chief Scientific and Medical Officer
Brian Lenz

Brian Lenz

Vice President, Chief Financial Officer
Eric I. Richman

Eric I. Richman

Director & Chairperson
Jerrold B. Grossman

Jerrold B. Grossman

Founder and Vice Chairman
Show more

ADMA Biologics Office Locations

ADMA Biologics has offices in Ramsey and Boca Raton
Ramsey, (HQ)
465 NJ-17
Boca Raton,
5800 Park of Commerce Blvd
Show all (2)
Report incorrect company information

ADMA Biologics Financials and Metrics

ADMA Biologics Revenue

ADMA Biologics's revenue was reported to be $22.76 m in FY, 2017
USD

Revenue (Q3, 2018)

4.2m

Net income (Q3, 2018)

(15.1m)

EBIT (Q3, 2018)

(13.8m)

Market capitalization (4-Dec-2018)

229.0m

Closing stock price (4-Dec-2018)

4.9

Cash (30-Sep-2018)

42.4m

EV

212.8m
ADMA Biologics's current market capitalization is $229 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

3.1m5.9m7.2m10.7m22.8m

Revenue growth, %

93%21%49%

General and administrative expense

4.4m6.7m8.5m18.1m

R&D expense

9.3m7.0m7.7m6.2m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

1.1m1.6m1.5m1.4m1.5m1.3m1.9m2.1m2.3m2.9m2.6m3.4m4.7m4.0m4.7m4.2m

General and administrative expense

845.3k1.1m1.5m1.0m1.3m1.4m2.1m1.7m1.7m1.8m4.3m4.4m4.2m5.0m5.0m5.4m

R&D expense

1.4m4.3m1.8m1.5m1.4m1.5m2.1m2.0m3.4m1.7m1.2m1.4m1.8m1.3m1.5m1.3m

Operating expense total

3.6m7.2m5.1m4.4m4.7m4.8m6.5m6.3m7.8m6.7m8.6m11.8m19.2m20.6m18.1m18.0m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

26.1m17.2m10.4m9.9m43.1m

Accounts Receivable

384.0k924.5k1.0m3.9m

Inventories

1.7m1.7m3.4m5.0m12.6m

Current Assets

31.1m24.1m21.3m21.7m63.2m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

5.4m26.5m17.9m14.0m16.6m7.8m9.2m8.9m12.5m7.9m8.5m25.6m13.6m26.1m55.2m42.4m

Accounts Receivable

335.1k484.4k803.5k562.2k351.4k522.5k1.2m944.0k826.7k1.3m839.9k2.3m1.5m3.7m3.8m4.1m

Inventories

1.2m984.5k1.1m1.5m1.9m2.5m2.8m4.0m4.2m4.6m5.3m13.2m13.4m12.4m12.2m13.9m

Current Assets

7.1m30.8m26.5m22.6m31.0m27.1m25.2m17.4m29.5m25.4m15.7m44.3m31.4m46.4m73.6m62.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(15.5m)(16.8m)(18.0m)(19.5m)(43.8m)

Depreciation and Amortization

210.6k247.9k469.8k469.6k2.7m

Inventories

(403.5k)(39.7k)(1.7m)(1.6m)589.3k

Accounts Payable

1.6m(937.8k)308.7k476.8k2.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(2.7m)(5.9m)(9.9m)(13.2m)(3.6m)(8.3m)(13.4m)(4.6m)(10.6m)(15.0m)(6.5m)(30.8m)(17.8m)(32.6m)(47.7m)

Depreciation and Amortization

96.9k151.1k234.7k352.6k234.4k351.7k118.1k1.2m829.5k1.7m2.5m

Inventories

556.5k216.5k1.9m(744.1k)(1.1m)4.0m(763.6k)(1.2m)(288.3k)(201.5k)189.4k381.2k(1.2m)

Accounts Payable

(369.8k)(265.8k)1.8m(305.5k)311.9k2.5m1.0m689.4k1.3m5.2m(202.8k)(2.8m)(653.2k)
USDY, 2018

EV/EBIT

-15.4 x

EV/CFO

-4.8 x

Debt/Equity

0.7 x

Debt/Assets

0.2 x

Financial Leverage

2.9 x
Show all financial metrics
Report incorrect company information

ADMA Biologics News and Updates

ADMA Biologics Reports Third Quarter 2018 Financial Results

RAMSEY, N.J. and BOCA RATON, Fla., Nov. 08, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Imm…

ADMA Biologics Reports FDA Compliance Status for its Manufacturing Facility has Improved

FDA Inspection Database Confirms VAI Status of Boca Raton, FL Facility

ADMA Biologics Reports Second Quarter 2018 Financial Results

Key Regulatory & Manufacturing Milestones Achieved Key Regulatory & Manufacturing Milestones Achieved

ADMA Biologics Reports Successful Close-Out of its April 2018 FDA Compliance Inspection

FDA Establishment Inspection Report (“EIR”) Received FDA Establishment Inspection Report (“EIR”) Received

ADMA Biologics Receives PDUFA Date for BIVIGAM® Regulatory Submission

Prior Approval Supplement (“PAS”) to Amend the Biologics License Application (“BLA”) for BIVIGAM ® is Supported by Data and Documentation Prepared Using ADMA’s Optimized IVIG Manufacturing P rocess Demonstrating Robust Reproducibility and Manufacturing Consistency
Report incorrect company information

ADMA Biologics Blogs

ADMA Biologics Receives PDUFA Date for RI-002

Resubmission of Biologics License Application (“BLA”) Reinforces the Company’s Commitment to Commercialize Novel Therapies for Immune Compromised Patients to Address Unmet Medical Needs RAMSEY, N.J. and BOCA RATON, Fla., Oct. 17, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“AD…

ADMA Biologics Provides Regulatory Update for BIVIGAM®

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 11, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics …

ADMA BioCenters Receives FDA Approval for Third Plasma Collection Center

RAMSEY, N.J. and MARIETTA, Ga., Oct. 03, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immun…

ADMA Biologics Resubmits Biologics License Application for RI-002

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 01, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Im…

ADMA Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

RAMSEY, N.J. and BOCA RATON, Fla., Aug. 27, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Defic…

ADMA Biologics Announces Closing of $40M Public Offering

RAMSEY, N.J. and BOCA RATON, Fla., June 12, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”) announced today the closing of its previously announced underwritten public offering of 8,368,200 shares of its common stock at a public offering price of $4.78 per sh…
Show more

ADMA Biologics Company Life and Culture

Report incorrect company information

ADMA Biologics Frequently Asked Questions

  • When was ADMA Biologics founded?

    ADMA Biologics was founded in 2004.

  • Who are ADMA Biologics key executives?

    ADMA Biologics's key executives are Bryant E. Fong, Dov Goldstein and James Mond.

  • How many employees does ADMA Biologics have?

    ADMA Biologics has 92 employees.

  • What is ADMA Biologics revenue?

    Latest ADMA Biologics annual revenue is $22.8 m.

  • What is ADMA Biologics revenue per employee?

    Latest ADMA Biologics revenue per employee is $247.4 k.

  • Who are ADMA Biologics competitors?

    Competitors of ADMA Biologics include Mast Therapeutics, Sucampo Pharmaceuticals and Clinigen Group.

  • Where is ADMA Biologics headquarters?

    ADMA Biologics headquarters is located at 465 NJ-17, Ramsey.

  • Where are ADMA Biologics offices?

    ADMA Biologics has offices in Ramsey and Boca Raton.

  • How many offices does ADMA Biologics have?

    ADMA Biologics has 2 offices.